Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Paul Anthony Polansky, BSPharm, MBA
Executive VP & Chief Pharmacy Officer
Sanovia Corporation
Philadelphia, PA
Authored Items
Chronic Obstructive Pulmonary Disease: An Overview
John F. Devine, DO, FACP
,
Paul Anthony Polansky, BSPharm, MBA
September 2008, Vol 1, No 7
in
Clinical
Partial Compliance with Antipsychotics Increases Mental Health Hospitalizations in Schizophrenic Patients: Analysis of a National Managed Care Database
Chris M. Kozma, PhD
,
Paul Anthony Polansky, BSPharm, MBA
,
Peter J. Weiden, MD
January 2009, Vol 2, No 1
in
Clinical
Increased Patient Cost-Sharing, Weak US Economy, and Poor Health Habits: Implications for Employers and Insurers
Melinda C. Haren, RN
,
Paul Anthony Polansky, BSPharm, MBA
,
Kirk McConnell
,
Arthur F. Shinn, PharmD, FASCP
April/May 2009, Vol 2, No 3
in
Business
Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis
Kim Saverno, PhD
,
Paul Anthony Polansky, BSPharm, MBA
,
Brian Seal, PhD
,
Michael J. Goodman, PhD
,
Kellie Meyer, PharmD
November/December 2009, Vol 2, No 7
in
Clinical
Last modified: September 6, 2013